Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.11
Ask: 0.14
Change: 0.00 (0.00%)
Spread: 0.03 (27.273%)
Open: 0.125
High: 0.125
Low: 0.125
Prev. Close: 0.125
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

12 Jan 2022 07:00

RNS Number : 1374Y
Deltex Medical Group PLC
12 January 2022
 

12 January 2022

 

Deltex Medical Group plc

Issue of Equity

 

Deltex Medical Group plc (the "Group" or "Deltex Medical") (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today announces the issue of 2,400,000 ordinary shares (the "New Shares") in connection with the termination agreement of a former employee.

 

Admission

Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. It is expected that admission will take place and dealings in the New Shares will commence on AIM on or around 8.00 a.m. on 17 January 2022.

 

Total voting rights

Immediately following admission, the Company's issued share capital will be 587,343,796 ordinary shares of 1 pence each ("Ordinary Shares"). Deltex Medical does not hold any Ordinary Shares in treasury. The total voting rights figure, immediately following admission of the New Shares, of 587,343,796 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, Deltex Medical under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

Deltex Medical Group plc

01243 774 837

Nigel Keen, Chairman

 investorinfo@Deltexmedical.com

Andy Mears, Chief Executive

Natalie Wettler, Group Finance Director

Nominated Adviser and Broker

Arden Partners plc

0207 614 5900 

Paul Shackleton

 info@arden-partners.com

Benjamin Onyeama-Christie 

 

 

Joint Broker

Turner Pope Investments (TPI) Ltd

0203 657 0050

Andy Thacker

James Pope

 info@turnerpope.com

 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal Doppler monitoring (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. The technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic monitoring space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.

Clinicians would like to be able to monitor the haemodynamic status of awake patients not only in the operating room and intensive care departments. Our R&D programmes will provide the capability for Deltex Medical devices to be used in A&E, including, for example, for the rapid detection of sepsis, as well as on lower acuity wards or outside the hospital setting.

Deltex Medical is designing the next generation of non-invasive Doppler ultrasound devices that will be released onto the TrueVue platform and will accurately measure a non-sedated patient's haemodynamic status anywhere within the hospital and not just for elective surgical patients.

Group goal

Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia protocols for surgical patients, as well as treating ventilated intensive care patients, including ventilated COVID-19 patients. There is also a desire to start measuring haemodynamics on awake patients outside of the operating room or intensive care departments, such as in lower acuity units or in A&E. Our R&D programmes are targeting these broader applications. Consequently, the Group's focus is on maximising value from the opportunities associated with: the COVID-19 pandemic; the elective surgery backlog; the risks associated with sepsis; awake patients and the higher profile of haemodynamic monitoring which has arisen from recent consolidation in the sector.

The Group aims to provide clinicians with a modern, next generation, single 'haemodynamic workstation' platform which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's clinical condition as well as the skill and expertise of the user. Doing this will enable the Group to partner with healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and via agreements with approximately 40 distributors overseas.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFSEFFEESELF
Date   Source Headline
18th Apr 20087:00 amRNSCompletion of Funding Package
15th Apr 20087:01 amRNSCardioQ update
14th Apr 20087:01 amRNSCardioQ update
7th Apr 20087:01 amRNSFinal Results
7th Apr 20087:01 amRNSNew Non-Executive Director
3rd Apr 20087:00 amRNSCardioQ update
2nd Apr 20087:01 amRNSCardioQ update
28th Mar 20087:02 amRNSNTAH update
26th Mar 20087:02 amRNSCardioQ update
20th Mar 20087:00 amRNSNotice of Results
3rd Mar 20083:22 pmRNSODM meta - analysis
25th Jan 20083:58 pmRNSDirector/PDMR Shareholding
23rd Jan 20087:01 amRNSPositive Scientific Review
23rd Jan 20087:01 amRNSPre-close update
18th Jan 200811:41 amRNSHSJ Article
26th Nov 20079:03 amRNSDirector/PDMR Shareholding
21st Nov 20077:02 amRNSCardioQ Product Endorsement
31st Oct 20072:15 pmRNSTotal Voting Rights
22nd Oct 20079:01 amRNSHolding(s) in Company
16th Oct 20074:03 pmRNSAdditional Listing
1st Oct 20077:06 amRNSCardioQ announcement
25th Sep 200711:00 amRNSInterim Results - Replacement
25th Sep 20077:03 amRNSInterim Results
16th Aug 20073:53 pmRNSAIM Rule 26 Information
31st Jul 20073:29 pmRNSTotal Voting Rights
25th Jul 200711:30 amRNSRecommendation for CardioQ
11th Jul 20077:01 amRNSTrading Statement
5th Jul 20073:30 pmRNSImproving Surgical Outcomes
29th Jun 20073:34 pmRNSDirector/PDMR Shareholding
29th Jun 20073:26 pmRNSAdditional Listing
29th Jun 20078:52 amRNSTotal Voting Rights
28th Jun 20077:04 amRNSNew Clinical Evidence
22nd Jun 20077:01 amRNSAdditional Listing
19th Jun 20073:02 pmRNSHolding(s) in Company
14th Jun 20074:02 pmRNSAdditional Listing
7th Jun 20077:03 amRNSNew CardioQ Data
5th Jun 20077:02 amRNSUS Reimbursement Update
31st May 20078:49 amRNSTotal Voting Rights
23rd May 20077:32 amRNSUS Reimbursement Coverage
22nd May 20078:31 amRNSAdditional Listing
3rd May 20071:06 pmRNSIssue of Equity
3rd May 200710:25 amRNSAGM Statement
12th Apr 20077:01 amRNSUCLH adopts CardioQ
28th Mar 20078:00 amRNSHealth Technology Assessment
21st Mar 20072:53 pmRNSHolding(s) in Company
15th Mar 20077:05 amRNSUS Government HTA Published
15th Mar 20077:01 amRNSFinal Results
9th Mar 200712:35 pmRNSHolding(s) in Company
2nd Mar 20073:56 pmRNSDeltex SupraQ Demo Invite
28th Feb 20075:20 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.